



MESI

Simplifying Diagnostics

Peripheral Arterial Disease An underdiagnosed condition



Information for general practitioners

Peripheral Arterial Disease (PAD) is a frequent but underdiagnosed condition, often with severe consequences. They include death, stroke, coronary heart disease, amputations, dementia and cognitive impairment.

The latest AHA Scientific Statement recommends that PAD screening with ABI is urgently implemented in high-risk populations. TBI or simultaneous measurement of ABI and TBI should be employed if suspecting medial artery calcification, e.g. in cases of chronic kidney disease (CKD) or diabetes^[1].

Why screen for PAD?

PAD

PAD PREVALENCE

More than **230 million** adults worldwide suffer from PAD.^[1]



RISK GROUPS

It is advisable to perform PAD screenings in patients of all risk groups.

<50

Patients under 50 with family history of PAD

<65

Patients under 65 with one or more of the following cardiovascular risk factors:



Hypertension



Overweight



Diabetes



Smoking




High cholesterol

65+

Everyone over 65



Leg pain while walking




Effect of smoking

> SMOKERS:

2x greater risk of PAD compared to non-smokers


> FORMER SMOKERS:

it takes up to 30 years for the PAD risk to reach the non-smoker level.^[1]



Effect of combination of risk factors

The duration of hypercholesterolemia and diabetes, the severity of hypertension, and cumulative intensity of smoking show graded relationships with PAD risk.^[2]



70% of patients with PAD do not experience symptoms and are thus not diagnosed. The TASC II consensus document recommends Ankle-Brachial Index measurement for all PAD risk groups.^[3]

ANKLE-BRACHIAL INDEX

A simple tool in detecting PAD

The Ankle-Brachial Index (ABI) is an effective comparison of blood pressure in the legs and the arms. It is non-invasive and painless. Using MESI mTABLET ABI, the procedure is quick and simple. Therefore, the test can be implemented routinely in both primary and specialised care. The ABI test is extremely important for two reasons:

It is a reliable predictor of the occlusion of arteries in the extremities – PAD. PAD detection is even more important because over 70% of the patients are asymptomatic.

Due to a high co-occurrence of PAD with other diseases, diagnosed patients have a great chance of early diagnosis of the other diseases such as:

- > coronary artery disease (CAD) or cerebrovascular disease (CVD): 32% [4],
- > renal insufficiency (RI): 39.7% [5],
- > diabetes: 49.7% [6],
- > metabolic syndrome: 58% [7]/63% (45+) [8],
- > hypertension: 35–55% [9],
- > hypercholesterolemia: 60% [10].



ABI reference scale

NON-COMPRESSIBLE

1.41 or more

NORMAL

1.40 - 1.00

BORDERLINE

0.99 - 0.91

ABNORMAL

0.90 - 0.51

SEVERE

0.50 or less

MESI mTABLET ABI

Pulse Waveform Recording



Normal result

The oscillation graph forms a clear lemon shape. This means that the arteries are elastic and that they responded to being briefly compressed by the cuff. The pulse waveforms have these characteristics:

- 1 A rapid rise in the upstroke during systole
- 2 A very sharp peak
- 3 A gradual downstroke
- 4 A presence of dichroic notch

Abnormal result

A flattened pulsewave recording or one without the typical lemon shape is an indicator of severe PAD.

The absence of the pulsations caused by occlusions in the artery makes it impossible to calculate the ankle pressures. Instead of the ABI value, the device will display a "PAD" result.

FLATTENED PULSEWAVE RECORDING



ESC RECOMMENDATIONS ^[11]

CLASS ^A

LEVEL ^B

Measurement of the ABI is indicated as a first-line non-invasive test for screening and diagnosis of LEAD.

I

C

In the case of incompressible ankle arteries or ABI > 1.40, alternative methods such as the Toe-Brachial Index, Doppler waveform analysis or pulse volume recording are indicated.

I

C

ABI = Ankle-Brachial Index
LEAD = Lower-Extremity Artery Disease

^A Class of recommendation
^B Level of evidence

MESI mTABLET TBI

The Toe-Brachial Index (TBI) is used in diagnosing PAD:

- when the ABI measurement cannot be interpreted or is inadequate
- with non-compressible arteries in the legs (diabetes, insufficiency-related calcification)
- in patients with excruciating pain in the lower extremities
- in end-stage renal disease
- in patients undergoing dialysis
- in very advanced age
- in patients with extensive wounds
- and/or in patients with lymphedema



REFERENCES

1. Criqui MH, Matsushita K, Aboyans V, Hess CN, Hicks CW, Kwan TW, McDermott MM, Misra S, Ujueta F; on behalf of the American Heart Association Council on Epidemiology and Prevention; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; Council on Lifestyle and Cardiometabolic Health; Council on Peripheral Vascular Disease; and Stroke Council. Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions: a scientific statement from the American Heart Association. *Circulation*. 2021; doi: 10.1161/CIR.0000000000001005
2. Joosten MM, Pai JK, Bertola ML, et al. Associations between conventional cardiovascular risk factors and risk of peripheral artery disease in men. *JAMA*. 2012;308(16):1660-1667. doi:10.1001/jama.2012.13415
3. Norgren L, Hiatt W R, Dormandy J A, et al. TASC II Working Group. Inter-society consensus for the management of peripheral arterial disease. *Int Angiol*. 2007;26(2):81-157
4. Francisco J, Serrano H et al.: Enfermedad arterial periférica: aspectos fisiopatológicos, clínicos y terapéuticos; *Rev Esp Cardiol*. 2007;60:969-82
5. Tranche Iparraguirre S et al: Enfermedad arterial periférica e insuficiencia renal: una asociación frecuente; *Nefrología (Madri)* vol. 32 N.º 3, Madrid 2012
6. Silbernagel G et al.: Prevalence of type 2 diabetes is higher in peripheral artery disease than in coronary artery disease patients; *Diabetes & Vascular Disease Research* 2015, Vol. 12(2) 146-149
7. Gorter P et al.: Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm; *Atherosclerosis Journal*, April 2004, Volume 173, Issue 2, pp. 361-367
8. Estirado E et al.: Síndrome metabólico en pacientes con enfermedad arterial periférica; *Rev Clin Esp*.2014;214:437-44
9. Makin A et al.: Peripheral vascular disease and hypertension: a forgotten association?; *Journal of Human Hypertension* (2001) 15, 447-454
10. Olin J W et al.: Peripheral Artery Disease: Current Insight Into the Disease and Its Diagnosis and Management; *Mayo Clinic Proceedings*. 2010 Jul; 85(7): pp. 678-692
11. Aboyans et al., 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS), chapter 10.2 Diagnostic tests.

Choose **MESI** for comprehensive arterial assessment



Why **MESI mTABLET ABI?**

- SmartArm™ detection – to determine the higher blood pressure of the two
- Automated, 3-cuff simultaneous measurement
- Multiple cuff sizes and ability to mix-and-match different size cuffs during one measurement
- Pulse waveforms and oscillation graphs
- Advanced review and alerts thanks to PADsense™ algorithm

Why **MESI mTABLET TBI?**

- Safe, simultaneous measurements in both arms and toes, with adaptive, infrared LED PPG light, detecting toe skin temperature and thickness
- FirstWave™ algorithm for detecting the first returning pulse waveform in the toes
- Comprehensive and reliable TBI report with pulse waveforms and oscillation graphs for the arms and PPG pulse waveforms for the toes
- Availability of single-use (disposable) toe cuffs

Expand the use of your **ABI** and **TBI** devices through smart applications

ABI Ankle-Brachial Index	TBI Toe-Brachial Index	BP Blood Pressure
DBP Dual Blood Pressure	PWV Pulse Wave Velocity	aBP Averaging Blood Pressure
Protocol Health Assessment Protocol	Worklist Patient Worklist	Photo Camera App

**BOOK A
DEMONSTRATION**

MESI, Ltd.
Leskoškova cesta 11a
1000 Ljubljana,
Slovenia, EU

www.mesimedical.com

f MESIdoo

in MESI



European production
and development



Worldwide presence

FDA

Food and Drug
Administration
cleared

MDR

EU Medical Device
Regulations
compliant



ISO 9001 Q-1664
ISO 13485 M-049

ISO 9001 and
ISO 13485 certified



MDSAP compliant

E: info@mesimedical.com
T: +386 1 620 34 87